Congress’ Oxycontin concerns continue
Executive Summary
Reps. Frank Wolf (R-Va), Jim Greenwood (R- Pa), Henry Bonilla (R-Texas) and Harold Rogers (R- Ky) meet with FDA Commissioner McClellan April 3 to discuss abuse of Purdue's OxyContin (oxycodone). Wolf sent a letter to HHS Secretary Thompson March 28 asking that OxyContin treatment be limited to patients with severe pain. The House Energy & Commerce committee is investigating OxyContin and Purdue's Palladone, a pain therapy pending at FDA (1"The Pink Sheet" March 3, p. 33)...
You may also be interested in...
Purdue Palladone Risk Management Documents Requested By House Cmte.
Purdue Pharma will submit documents relating to risk management for its pending pain therapy Palladone to the House Energy & Commerce Committee
Advanz Pharma Agrees Sale In Largest European Deal Since COVID-19 Pandemic
Three years after rebranding from Concordia, Advanz Pharma is to be swallowed up by European-focused private equity Nordic Capital.
Consumer Genome Sequencing Being Applied To Covid-19 New Variants In UK
The goal is to create a program which mass sequences SARS-CoV-2 samples in order to detect new variants, with £30m injected into the UK's hub for genomic sequencing in Cambridge.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: